Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 7/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | STAT3 | P40763 | 6/20 | 0.46 |
| ▸ | GIPR | P48546 | 3/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2653432 | 0.96 | GCGR (0.57) | GCGRALDH1A1MAPTSMN1; SMN2STAT3 | |
| SCHEMBL2655713 | 0.90 | GCGR (0.59) | GCGRSTAT3GIPRFAAHEPHX2 | |
| SCHEMBL2663286 | 0.84 | GCGR (0.80) | GCGRGIPR | |
| SCHEMBL2652178 | 0.84 | GCGR (0.80) | GCGRGIPR | |
| SCHEMBL2653661 | 0.82 | GCGR (0.65) | GCGRSTAT3GIPR | |
| SCHEMBL2663127 | 0.81 | GCGR (0.64) | GCGRGIPR | |
| SCHEMBL2650960 | 0.79 | ALDH1A1 (0.47) | GCGRALDH1A1MAPTSMN1; SMN2GIPR | |
| SCHEMBL4092561 | 0.77 | TDP1 (0.46) | GCGRGIPRSCN9ATDP1L3MBTL1 | |
| SCHEMBL4096390 | 0.77 | TDP1 (0.46) | GCGRGIPRSCN9ATDP1L3MBTL1 | |
| SCHEMBL6293030 | 0.76 | STAT3 (0.48) | GCGRALDH1A1MAPTSMN1; SMN2STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152750-A1 | Novel glucagon antagonists | NOVO NORDISK A/S (DK) | 2004-08-05 | — | — | US | disclosed |
| WO-2004056763-A2 | NOVEL GLUCAGON ANTAGONISTS | NOVO NORDISK A/S (DK) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152750-A1 | Novel glucagon antagonists | GLP1R, GCGR, GIPR | GCGR 2/4885ALDH1A1 4823/4885MAPT 4592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.